927TiP SKYSCRAPER-09: A phase II, randomised, double-blinded study of atezolizumab (Atezo) + tiragolumab (Tira) and atezo + placebo as first-line (1L) therapy for recurrent/metastatic (R/M) PD-L1+ squamous cell carcinoma of the head and neck (SCCHN)
Ezra E.W. Cohen(Moores Cancer Center), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), G. Goodman, Jérôme Fayette(Université Claude Bernard Lyon 1), Lisa Licitra(University of Milan), Melissa L. Johnson(Tennessee Oncology), Deborah J. Wong(University of California, Los Angeles), Katarina Cvijović(Roche (Switzerland)), Nuttapong Ngamphaiboon(Mahidol University), Yongmin Yan(Jiangsu University), L. Wang(Statistical Research (United States)), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), SH Lee(Samsung Medical Center), H-F. Kao(National Taiwan University Hospital), K.M. Komatsubara, M. Afshari, A. Psyrri(University General Hospital Attikon), Timothy Pham(Nvidia (United States)), Huarong Tang(IQVIA (United States)), Christina Matheny
Cited by 4
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
|Journal of Clinical Oncology|2008|1.6k